 Connection
Natalie Serkova to Adult
This is a "connection" page, showing publications Natalie Serkova has written about Adult.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.101 |
|
|
|
-
Serkova NJ. Imaging biochemistry noninvasively: magnetic resonance spectroscopy in liver disease. JPEN J Parenter Enteral Nutr. 2009 Nov-Dec; 33(6):726-8.
Score: 0.020
-
Tissot van Patot MC, Murray AJ, Beckey V, Cindrova-Davies T, Johns J, Zwerdlinger L, Jauniaux E, Burton GJ, Serkova NJ. Human placental metabolic adaptation to chronic hypoxia, high altitude: hypoxic preconditioning. Am J Physiol Regul Integr Comp Physiol. 2010 Jan; 298(1):R166-72.
Score: 0.020
-
Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, Sullivan H, Hedlund T, Crawford ED. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate. 2008 May 01; 68(6):620-8.
Score: 0.018
-
Serkova N, Bendrick-Peart J, Alexander B, Tissot van Patot MC. Metabolite concentrations in human term placentae and their changes due to delayed collection after delivery. Placenta. 2003 Feb-Mar; 24(2-3):227-35.
Score: 0.012
-
Weitzel LB, Ambardekar AV, Brieke A, Cleveland JC, Serkova NJ, Wischmeyer PE, Lowes BD. Left ventricular assist device effects on metabolic substrates in the failing heart. PLoS One. 2013; 8(4):e60292.
Score: 0.006
-
Yap TA, Arkenau HT, Camidge DR, George S, Serkova NJ, Gwyther SJ, Spratlin JL, Lal R, Spicer J, Desouza NM, Leach MO, Chick J, Poondru S, Boinpally R, Gedrich R, Brock K, Stephens A, Eckhardt SG, Kaye SB, Demetri G, Scurr M. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clin Cancer Res. 2013 Feb 15; 19(4):909-19.
Score: 0.006
-
Cohen MJ, Serkova NJ, Wiener-Kronish J, Pittet JF, Niemann CU. 1H-NMR-based metabolic signatures of clinical outcomes in trauma patients--beyond lactate and base deficit. J Trauma. 2010 Jul; 69(1):31-40.
Score: 0.005
-
Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010 Feb 10; 28(5):780-7.
Score: 0.005
-
Tissot van Patot MC, Serkova NJ, Haschke M, Kominsky DJ, Roach RC, Christians U, Henthorn TK, Honigman B. Enhanced leukocyte HIF-1alpha and HIF-1 DNA binding in humans after rapid ascent to 4300 m. Free Radic Biol Med. 2009 Jun 01; 46(11):1551-7.
Score: 0.005
-
Lam ET, O'Bryant CL, Basche M, Gustafson DL, Serkova N, Baron A, Holden SN, Dancey J, Eckhardt SG, Gore L. A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Mol Cancer Ther. 2008 Dec; 7(12):3685-94.
Score: 0.005
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|